Peijia Medical Reports Impressive Financial Performance for 2025

Peijia Medical (9996.HK), a prominent Chinese company specializing in cutting-edge transcatheter valve therapeutics and neurovascular interventions, recently disclosed its financial results for the first half of 2025. The results, released on August 22, 2025, reflect the company's robust growth and operational improvements, setting a positive tone for its future endeavors.

Financial Highlights

During the reporting period, Peijia Medical demonstrated sustainable revenue growth, achieving a remarkable RMB353.4 million, representing a 17.3% increase from the previous year. This growth can be attributed to the strong performance of both the transcatheter aortic valve replacement (TAVR) products and neurointerventional products, which accounted for 45.7% and 54.3% of revenue, respectively.

The TAVR product line saw a notable rise in revenue, which jumped 24.0% to RMB161.6 million. This surge was bolstered by increased market share in China's transfemoral TAVR segment, alongside a favorable shift towards newer premium offerings. On the neurointerventional side, revenue climbed 12.2% to RMB191.8 million, driven by greater market penetration and the successful rollout of the YonFlow® Flow Diverting Stent.

Efficient cost management and economies of scale allowed Peijia to dramatically enhance its operational performance. The profit from the Neurointerventional Business segment soared by 42.4% to RMB40.9 million, while the losses for the TAVR segment narrowed considerably by 35.3% to RMB76.1 million. Excluding losses from the Future Technology Business, the group's core net loss was reduced by 52.4%, reaching RMB30.7 million.

Milestone Achievements

A standout achievement for Peijia during the reporting period was the Transcatheter Valve Therapeutic Business achieving its first-ever commercial profit of RMB29.1 million. The company expanded its hospital distribution network significantly, with over 720 medical institutions now utilizing its TAVR products. Total implant volumes exceeded 2,050 units, marking an impressive growth of 18.8%.

Peijia has also upgraded its TAVR offerings with new models, including the TaurusOne®, TaurusElite®, and TaurusMax™, providing a comprehensive set of options for varying patient needs. The innovative TaurusMax™ has garnered favorable clinical feedback for its revolutionary 3D-steering technology, indicating strong market potential and impact.

Through strategic operational improvements and a keen focus on productivity, selling and distribution expenses for the TAVR segment declined by 8.3%, with the expense ratio seeing a significant reduction of 21.8 percentage points to 61.9%.

Innovations and Future Prospects

Looking ahead, Peijia Medical is poised for continued success, with three core pipeline products nearing registration alongside several other key technologies making significant strides. These include the TaurusTrio™, TaurusNXT®, and GeminiOne® systems, all of which have demonstrated promising safety and efficacy in clinical trials.

Recent advancements have led to the acceptance of the registration application for TaurusTrio™ by the National Medical Products Administration (NMPA), with plans to submit for TaurusNXT® and GeminiOne® in the coming months. Anticipated approvals for these products are expected between late 2025 and mid-2026.

Additionally, the company's Neurointerventional Business remains on a trajectory of growth, with strong sales from the DCwire® Micro Guidewire and the successful market entry of YonFlow® Flow Diverting Stent.

Chairman and CEO Dr. Yi Zhang emphasized the significance of the first half of 2025, stating, “We achieved simultaneous revenue growth, operational efficiency, and cost reduction. Our Transcatheter Valve Therapeutic Business has reached a crucial milestone with the first commercial profit, while our Neurointerventional Business continues its profitable expansion.”

Peijia Medical is distinctly focused on leading the industry with its innovative technologies while ensuring high-quality therapeutic solutions for patients globally. The company’s commitment to innovation and operational excellence positions it well for sustained growth, creating lasting value for shareholders and stakeholders alike.

In summary, Peijia Medical's interim results paint a positive picture of its business trajectory, innovations in technology, and commitment to improving patient care through advanced medical devices.